Bellary, Srikanth and Barnett, Anthony H (2023). SGLT2 inhibitors in older adults: overcoming the age barrier. The lancet. Healthy longevity, 4 (4), e127-e128.
Publication DOI: | https://doi.org/10.1016/S2666-7568(23)00039-9 |
---|---|
Divisions: | College of Health & Life Sciences > School of Biosciences College of Business and Social Sciences > Aston Business School > Aston India Centre for Applied Research College of Health & Life Sciences College of Health & Life Sciences > Chronic and Communicable Conditions Aston University (General) |
Additional Information: | Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This article refers to: Pratley, Richard E. et al (2023) Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. The Lancet Healthy Longevity, Volume 4, Issue 4, e143 - e154. https://doi.org/10.1016/S2666-7568(23)00032-6 |
Uncontrolled Keywords: | Aged,Hypoglycemic Agents - therapeutic use,Humans,Diabetes Mellitus, Type 2 - drug therapy,Sodium-Glucose Transporter 2 Inhibitors - therapeutic use |
Publication ISSN: | 2666-7568 |
Last Modified: | 16 Dec 2024 08:51 |
Date Deposited: | 17 Apr 2023 09:13 |
Full Text Link: |
https://www.the ... 0039-9/fulltext |
Related URLs: |
http://www.scop ... tnerID=8YFLogxK
(Scopus URL) |
PURE Output Type: | Letter |
Published Date: | 2023-04 |
Accepted Date: | 2023-03-06 |
Submitted Date: | 2023-03-06 |
Authors: |
Bellary, Srikanth
(
0000-0002-5924-5278)
Barnett, Anthony H |
Download
Version: Published Version
License: Creative Commons Attribution Non-commercial No Derivatives
| Preview